4-(4-(3,5-dichloro-4-ethoxyphenyl)thiazol-2-yl)benzoic acid

ID: ALA4539676

Chembl Id: CHEMBL4539676

PubChem CID: 155550105

Max Phase: Preclinical

Molecular Formula: C18H13Cl2NO3S

Molecular Weight: 394.28

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCOc1c(Cl)cc(-c2csc(-c3ccc(C(=O)O)cc3)n2)cc1Cl

Standard InChI:  InChI=1S/C18H13Cl2NO3S/c1-2-24-16-13(19)7-12(8-14(16)20)15-9-25-17(21-15)10-3-5-11(6-4-10)18(22)23/h3-9H,2H2,1H3,(H,22,23)

Standard InChI Key:  UEAUHRIJWPLYQI-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4539676

    ---

Associated Targets(non-human)

Rarb Retinoic acid receptor beta (93 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rara Retinoic acid receptor alpha (153 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rarg Retinoic acid receptor gamma (95 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 394.28Molecular Weight (Monoisotopic): 392.9993AlogP: 5.88#Rotatable Bonds: 5
Polar Surface Area: 59.42Molecular Species: ACIDHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.84CX Basic pKa: 1.50CX LogP: 5.75CX LogD: 2.51
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.59Np Likeness Score: -1.34

References

1. Goncalves MB, Clarke E, Jarvis CI, Barret Kalindjian S, Pitcher T, Grist J, Hobbs C, Carlstedt T, Jack J, Brown JT, Mills M, Mumford P, Borthwick AD, Corcoran JPT..  (2019)  Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.,  29  (8): [PMID:30792038] [10.1016/j.bmcl.2019.02.011]

Source